Developing Liquid Formulations for the Oral Dosing of Lipophilic Drugs

Published on: 


Tuesday, October 4, 2022 at 11am CDT |12pm EDT | 9am PDT Is developing formulations of highly lipophilic compounds worth the effort? With today’s excipients and technologies, the answer is a definite yes. This presentation will showcase the issues presented by lipophilic compounds and ways to address them.

Register Free:

Event Overview:
This presentation focuses on the development of non-aqueous liquid formulations for highly lipophilic compounds. Experts from Pace® Life Sciences dive into lipophilicity and its chemical and biopharmaceutical consequences; formulation strategies to allow oral dosing in both pre-clinical and clinical studies; and analytical differences between these types of molecules.
However, please be aware that non-aqueous formulations for other routes of administration (e.g., injection or topical) will not be covered in this presentation.

Key Learning Objectives:
Attendees will gain an understanding that:

  • The formulation challenges provided by highly lipophilic compounds can be managed using non-aqueous liquid vehicles
  • The same drug/vehicle formulation can be administered directly into animals or filled into capsule shells for human dosing
  • There can be some analytical challenges with this type of formulation

Who Should Attend:

  • Formulation scientists
  • Research and development (R&D) scientists
  • Quality control scientists
  • R&D managers


David Barnes, PhD
Vice President of Scientific Affairs
Pace® Life Sciences

Dave graduated with a degree in pharmacy from The School of Pharmacy, U. of London (“The Square”). After completing a year’s pharmacy internship, he returned to The School of Pharmacy to undertake a Ph.D. in Pharmaceutical Sciences.
Dave then joined Pfizer’s R&D division in Sandwich, England and for the next 13 years worked on developing drug products of locally discovered molecules, from early pre-formulation through scale-up and transfer into production sites in Europe and the US.
In 2001, with the acquisition of Parke-Davis, Dave moved to Ann Arbor to complete the construction and commissioning of the new Pharmaceutical Sciences building (550/TDF). Upon the successful start-up of the facility, he moved to the Clinical Trial Materials department managing activities across the Ann Arbor, Kalamazoo and Groton, CT sites.
In 2008, with the closure of the Ann Arbor facility, Dave teamed up with Gerry Cox to set up Velesco Pharmaceutical Services which provides formulation and analytical development services for small to medium sized pharma companies as well as the provision of small scale, non-sterile cGMP supplies for early-stage clinical studies.
In 2021 Velesco became a part of the Pace® Life Sciences laboratory network. Dave is now Vice President of Scientific Affairs at Pace® Life Sciences in Wixom, MI.

Register Free: